L. Moesbergen

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T‐lymphocytes and preserved MHC class I antigen expression

Erik Hooijberg, T. D. de Gruijl, P. V. van Leeuwen, 2008, International journal of cancer.

Absence of Granzyme B Positive Tumour-Infiltrating Lymphocytes in Primary Melanoma Excisional Biopsies is Strongly Associated with the Presence of Sentinel Lymph Node Metastasis

C. Meijer, T. D. de Gruijl, P. V. van Leeuwen, 2009, Cellular oncology : the official journal of the International Society for Cellular Oncology.

Expression of c‐FLIP is primarily detected in diffuse large B‐cell lymphoma and Hodgkin’s lymphoma and correlates with lack of caspase 8 activation

C. Meijer, E. Hooijberg, C. Meijer, 2007, Histopathology.

Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients

C. R. Leemans, C. Meijer, T. D. de Gruijl, 2013, Journal of Translational Medicine.

18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair

J. Vose, A. Buck, O. Hoekstra, 2014, EJNMMI Research.

ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2

C. Meijer, S. E. Verbrugge, G. Jansen, 2015, Haematologica.

MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL

Stefan P. Glaser, A. Strasser, David C. S. Huang, 2016, Cell Death and Disease.

Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition

A. Bloem, M. Minnema, V. Peperzak, 2021, Haematologica.

Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma.

R. Raymakers, M. Minnema, V. Peperzak, 2021, Blood advances.

Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells

M. Kersten, M. Minnema, E. Eldering, 2021, Cell Death & Disease.

Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.

P. Sonneveld, P. A. von dem Borne, M. Minnema, 2019, Blood advances.